Soft Mist Inhaler

Designed for the treatment of chronic obstructive pulmonary disease (COPD), lower respiratory tract infections, and chronic respiratory diseases, this device enables uniform aerosolization of high value pharmaceuticals and precise delivery to targeted regions of the lungs. Its intuitive operation minimizes the need for hand mouth coordination and inspiratory effort, significantly improving ease of use and patient adherence.

Featuring a mist velocity of 0.8 m/sec and an aerosol duration of 1.5 seconds, the system enhances pulmonary drug with liposomal, biologic, mRNA, protein, antibody drug conjugates (ADC) and small / largemolecule formulations. deposition and bioavailability while reducing systemic side effects. The fully mechanical, propellant free design aligns with international sustainability initiatives and pharmaceutical development requirements.

Drug Development Ready

Features 

+ Semiconductor Process Customized Low Shear Microfluidic Channels

With critical linewidths < 3 µm and precision of 0.3 µm, filtration channels and atomization nozzles are integrated into a silicon/glass chip. The low-shear transport mechanism preserves molecular integrity, enabling highly uniform aerosol generation and improved lung deposition efficiency.

+ velocity 0.8 m/sec with an aerosol duration of up to 1.5 seconds

Slow, sustained soft mist release, allowing medication to deposit deeper in the lungs. The low resistance nebulization design ensures patient friendly operation and improves treatment adherence.

+ Eco Friendly

No CFC or HFA propellants, no electricity required. A spring powered mechanical system delivers consistent aerosolization, while the replaceable drug cartridge design supports diverse pharmaceutical applications.

+ In Vitro Performance Testing for Inhalation Products

Our Laboratory is accredited to ISO/IEC 17025 and ISO 27424, and complies with EN ISO 27427, EP <0671>, EP <2.9.18>, EP <2.9.44>, USP–NF <601>, and USP–NF <1601> standards. Bioequivalence related testing services.

• ➤ Aerodynamic particle size distribution
• ➤ Fine particle fraction (FPF)
• ➤ Delivered dose uniformity
• ➤ Spray pattern and plume geometry
• ➤ Aerosol duration
• ➤ Cloud velocity

Global IP Strategy & Patent Risk Management

Protects critical manufacturing processes and core technologies while mitigating infringement risks. This strategy extends product life cycles, enables next generation inhaled drug delivery platforms, and establishes long term, defensible competitive advantages.